Most common systemic agents for advanced HCC.
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver, and the second leading cause of cancer-related mortality worldwide with a very poor 5-year survival. Treatment for HCC includes surgery, liver-directed therapies and systemic therapies. Until 2008, no effective systemic therapy was available for advanced HCC. Sorafenib is the first drug to show improvement in overall survival among patients with advanced HCC in comparison to placebo, and it is approved by U.S. Food and Drug Administration (FDA) as a first-line treatment of advanced HCC. After sorafenib approval, several targeted and immune therapies were tested and showed efficacy in advanced HCC. Lenvatinib has been shown to be non-inferior to sorafenib as first-line treatment. Both nivolumab and regorafenib showed improvement in overall survival among patients with advanced HCC as a second line treatment after progression on sorafenib, and both are FDA approved for this indication. There is a limited role for cytotoxic agents in the treatment of advanced HCC.
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver. HCC is the second leading cause of cancer-related mortality worldwide with a very poor 5-year survival. The incidence of HCC has been increasing over the past decades . Risk factors for HCC include hepatitis B and C infection, alcohol use, non-alcoholic steatohepatitis, and aflatoxin. Treatment approaches for HCC depend on the stage and the hepatic function, and includes surgical therapies (liver transplantation, resection, and ablation) and nonsurgical therapies, which may be liver-directed (percutaneous ethanol injection, radiofrequency ablation, transarterial embolization, external beam radiation therapy) or systemic therapies.
Until 2008, there was no effective systemic therapy for advanced HCC. Cytotoxic chemotherapy has not been used routinely as of low efficacy and poor functional status for patients with advanced HCC, who often have cirrhosis. Since the advent of sorafenib in 2008, there has been a surge of several targeted and immune therapies with various degree of effectiveness. In this chapter, systemic therapies for advanced HCC will be reviewed. Those include oral kinase inhibitors, antiangiogenic monoclonal antibodies, immune-therapeutic approaches and cytotoxic chemotherapies.
2. Kinase inhibitors
Sorafenib is a multi-kinase inhibitor of vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptor (PDGFR) and Raf family kinases . Sorafenib has shown to improve overall survival in comparison to placebo in advanced HCC, and it was the first drug to get Food and Drug Administration (FDA) approval as a first-line treatment for Child-Pugh score-A HCC. In the multicenter European SHARP trial, 602 inoperable HCC and Child-Turcotte-Pugh-A cirrhosis patients, were assigned to sorafenib (400 mg twice daily) or placebo . The primary endpoint of the trial was overall survival, which was significantly longer in the sorafenib-treated group (10.7 vs. 7.9 months). Time to radiologic progression was also longer (5.5 vs. 2.8 months). Objective response rates were low at 2%.
Sorafenib was well tolerated in this trial. Diarrhea and hand-foot skin reaction were the only grade 3 or 4 adverse effects that occurred significantly more often in the treated group; (8 vs. 2%) and (8 vs. <1%) respectively. There were no differences in liver dysfunction or bleeding.
An exploratory analysis of SHARP trial showed that hepatitis C related HCC has the highest median overall survival advantage of 6.6 months (14 vs. 7.4 months). This is in comparison to 3.6 months (9.7 vs. 6.1 months) in those with HBV related cirrhosis and 2.3 months (10.3 vs. 8 months) in those with alcohol-related liver disease .
Hepatitis B virus is more prevalent in the Asian patients than in the Western population. Sorafenib was tested as a first-line treatment in Asian patients in a placebo-controlled phase III trial in which 226 patients with Child-Turcotte-Pugh A cirrhosis received sorafenib 400 mg twice daily or placebo . Patients receiving sorafenib had significantly higher median overall survival (6.5 vs. 4.2 months). Grade 3 or 4 side effects were similar to SHARP trial.
Based on the results of SHARP trial, the FDA approved sorafenib monotherapy as first-line therapy for unresectable HCC.
It is worth mentioning that the patients enrolled in the above trials had mostly Child-Turcotte-Pugh A cirrhosis. This is not representative of the real practice where a significant number of patients have more advanced cirrhosis. FDA approval of sorafenib for HCC did not particularly specify the underlying cirrhosis state. Data regarding safety and efficacy of sorafenib in patients with Child-Turcotte-Pugh B or C cirrhosis are limited, and suggest that patients have poorer overall survival and overall worse side effect profile in comparison to patients with Child-Turcotte-Pugh A. Advanced progressive cirrhosis rather than sorafenib itself might be an explanation for such differences [6, 7].
Sorafenib is associated with several side effects such as hypertension, cardiotoxicity, arterial thromboembolism, bleeding, renal toxicity, hand-foot skin reaction and others. Sorafenib has been associated with potentially fatal liver toxicity. Liver function tests should regularly be monitored during treatment.
2.1.1. Combining sorafenib with doxorubicin
In a phase II trial, the combination of six cycles of doxorubicin with sorafenib 400 mg twice daily was compared to sorafenib and placebo . Combination therapy was associated significantly longer median time to tumor progression (6.4 vs. 2.8 months) and median overall survival duration (13.7 vs. 6.5 months). The side effect profile was not significantly worse with combined therapy. However those results were not reproduced in the randomized phase III trial, Cancer and Leukemia Group B [CALGB] trial 80,802 . The study was stopped early by the data monitoring safety board after a planned interim analysis suggested futility for the combination. In a preliminary report presented at the 2016 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, median overall survival was not significantly better for the combination (9.3 vs. 10.5 months), nor was median progression-free survival (3.6 vs. 3.2 months), but toxicity was worse.
Lenvatinib is a multi-kinase inhibitor of VEGFRs, fibroblast growth factor receptors (FGFR), (PDGFR), c-Kit, and the RET proto-oncogene .
A randomized noninferiority trial, the REFLECT study, compared lenvatinib (12 mg once daily for body weight ≥60 kg, 8 mg daily for <60 kg) with sorafenib (400 mg daily for all patients) in 954 patients with unresectable HCC and no prior systemic therapy (99% Child-Turcotte-Pugh A) . The predefined noninferiority margin (primary endpoint overall survival) was 1.08. Lenvatinib was noninferior to sorafenib (median overall survival 13.6 vs. 12.3 months, hazard ratio 0.92, 95% CI 0.79–1.06), the objective response rate was higher (24 vs. 9%), and median time to progression was longer (7.4 vs. 3.7 months, hazard ratio 0.66, 95% CI 0.57–0.77). Lenvatinib leads to higher grade 3 or 4 hypertension (23 vs. 14%), while sorafenib was associated with higher hand-foot skin reaction (11 vs. 3%).
Lenvatinib was approved in Japan in March 2018 for unresectable HCC. Lenvatinib is not approved by FDA yet.
Both sorafenib and lenvatinib can be used in the first-line treatment of advanced HCC. There are no data on second-line treatment after lenvatinib and whether lenvatinib is effective as a second line after sorafenib.
Regorafenib is an antiangiogenic (including VEGFR-1, VEGFR-2, and VEGFR-3), anti-stromal, and an oncogenic tyrosine kinase inhibitor that is structurally similar to sorafenib .
In the randomized RESORCE trial, 573 patients who received sorafenib for at least 20 days at a dose of at least 400 mg daily and who had radiologic progression were randomly assigned to regorafenib (160 mg once daily for 3 weeks on and 1 week off) or placebo . Regorafenib was associated with significantly higher median OS (10.6 vs. 7.8 months, hazard ratio for death 0.63) and disease control (objective response plus stable disease; 65 vs. 36%).
Treatment was relatively well tolerated; grade 3 or 4 hypertension, hand-foot skin disease and fatigue were more frequent with regorafenib. Sixty-eight percent of patients treated with regorafenib required dose modification for adverse events compared with 31% of the placebo group.
In April 2017, the FDA expanded the indications for regorafenib to include patients with HCC who had been previously treated with sorafenib.
Regorafenib is an alternative to nivolumab for second-line HCC treatment. There are no trials comparing regorafenib with nivolumab in this setting.
Cabozantinib is another inhibitor of several receptor tyrosine kinases, including the hepatocyte growth factor/c-MET and VEGFR . Efficacy in patients with previously treated advanced HCC was shown in the placebo-controlled phase III CELESTIAL trial . In a preliminary report, in the group of patients receiving second- or third-line treatment, median overall survival was significantly better with cabozantinib (10.2 vs. 8.0 months), and the difference was more pronounced when the analysis was limited to patients whose only prior therapy was sorafenib (median overall survival 11.3 vs. 7.2 months). The most common grade 3 or 4 adverse events with cabozantinib were palmar-plantar erythrodysesthesia (17 vs. 0 in the placebo group), hypertension (16 vs. 0%), increased aspartate aminotransferase (12 vs. 7%), fatigue (10 vs. 4%), and diarrhea (10 vs. 2%).
Axitinib is a selective kinase inhibitor that inhibits VEGFR. Axitinib was not superior to best supportive care alone in a randomized phase II trial comparing best supportive care plus axitinib (starting dose 5 mg twice daily) with placebo in 202 patients with advanced HCC who progressed on or were intolerant of one prior antiangiogenic therapy . The difference in median overall survival (the primary endpoint), was not statistically significant (12.7 vs. 9.7).
Sunitinib is another orally active multi-kinase inhibitor that targets a variety of tyrosine kinases in addition to VEGFR, including PDGFRs, KIT, RET, and FMS-like tyrosine kinase 3 (FLT3) .
Sunitinib was significantly inferior to sorafenib in a phase III trial that directly compared both drugs in 1073 previously untreated patients with advanced HCC . The trial was closed prematurely when an interim analysis revealed that patients receiving sunitinib had significantly worse survival (median 7.9 vs. 10.2 months) and more frequent and severe treatment-related toxicity.
3. Antiangiogenic monoclonal antibodies
Bevacizumab is a monoclonal antibody directed against VEGFR that has some activity in advanced HCC. Efficacy was shown in a trial in which 46 patients with advanced nonmetastatic HCC received single-agent bevacizumab at a dose of either 5 or 10 mg/kg once every other week . An objective response was documented in six (13%, one complete), and the median progression-free survival was 6.9 months. The most common grade 3 or 4 toxicities were hypertension (15%), thrombosis (6%), and major bleeding (11%).
Bevacizumab is also active in combination with capecitabine, with or without oxaliplatin [20, 21], and gemcitabine combined with oxaliplatin (GEMOX) . Whether any of those combination regimens are better than bevacizumab alone is not clear and will require randomized trials.
Ramucirumab is a recombinant monoclonal antibody that binds to VEGFR-2. The REACH trial failed to show a significant survival advantage relative to placebo (median overall survival 9.2 vs. 7.6 months) in patients with advanced HCC who progressed on sorafenib . An unplanned group analysis suggested a possible survival benefit in patients with a high initial level of alpha-fetoprotein (AFP) above 400 ng/mL) at diagnosis. A follow-up phase III trial in patients with AFP-elevated HCC is ongoing.
4. Immunotherapeutic approaches
Immune-based approaches that focus on vaccination strategies, cytokines or non-specific T cell activation have been tested for many years in HCC without promising result. However, the recent advancement in immune-oncology with the FDA approval of many immune checkpoint inhibitors, sparked a great interest in the immune-based treatment approaches for patients with HCC. The strategy of adopting an immunocentric approach to HCC treatment may be potentially more efficacious and less toxic. Interestingly, what makes the immunotherapy appealing in liver cancer is that HCC is a high immunogenic cancer, due to high blood flow with unique vast tumor antigen repertoire because of mutations and aberrant expression profiles . On the other hand, there is an inherently immunosuppressive microenvironment of the liver; “Tolerogenic Liver”; that helps evade the immune response. The liver’s pathway to immune tolerance is multifactorial. T-cells are stimulated through a dual signaling pathway that requires the interaction of T cell receptors (TCR) with major histocompatibility complex (MHC)/peptide complexes on antigen presenting cells (APCs) and expression of co-stimulatory molecules on T cells and APCs. Down-regulation of MHC class I molecules on tumor cells induces impairment of tumor antigen processing and presentation . In addition, a reduced expression of co-stimulatory molecules, such as B7-1 and B7-2, in HCC leads to T cell anergy . Programmed cell death protein-1 (PD-1) overexpression in tumors promotes immune evasion and tumor growth by suppressing T-cell response . PD-L1 is not the only immunosuppressive factor in the tumor microenvironment. HCC immune evasion can also be achieved through overexpression of MHC class II molecules in tumor cells, which leads to CD4+ T cell anergy in the absence of co-stimulatory molecules (CMs) on T cells and APCs. A better understanding of the antigenic profile of HCC and tumor microenvironment has helped to develop a refined immunotherapeutic strategies in treatment of HCC .
4.2. Indirect immunological strategies
4.2.1. Checkpoint inhibitors
Checkpoint Inhibitors play critical roles in cancer immunology. Blockading the PD-1/PD-L1 pathway could modulate the tumor microenvironment, reactive T-cell and prime the endogenous antitumor immune responses. Treatment with checkpoints inhibitors have shown benefits in clinical trials of HCC. Common immune checkpoint proteins include cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), PD-1, programmed cell death ligand one (PD-L1), lymphocyte activation gene three protein (LAG-3), B and T lymphocyte attenuator (BTLA), T-cell immunoglobulin and mucin-domain-containing (TIM-3), VISTA and OX40 [29, 30].
188.8.131.52. CTLA-4 inhibitors
CTLA-4 is constitutively expressed in activated T cells and NK cells . CTLA-4 inhibitors prevent the binding of CTLA-4 to B7-1 and B7-2, thereby actively encourage the activation of T cells. CTLA-4 was the first checkpoint studied in HCC. Tremelimumab, an anti-CTLA-4 monoclonal antibody, was tested in a phase II study in a 21 patients with advanced HCC and hepatitis C. The disease control rate was (76.4%), median OS and PFS were 7.5 and 6.4 months respectively. Moreover, viral loads of HCC were significantly reduced. Although a short-lived remarkable rise in serum transaminases was observed after the first dose, no patients experienced immune-related adverse events or serious hepatotoxicity . In another noncomparative clinical trial involving patients with advanced HCC, a combination therapy of tremelimumab and radiofrequency ablation increased the number of intratumoral CD8+ T cells and reduced HCV viral loads .
184.108.40.206. PD-1 inhibitors
The PD-L1/PD-1 pathway is another mechanism of tumor-induced immune tolerance. PD-1 expression on effecter phase CD8+ T cells is increased in patients with HCC compared to no HCC cirrhotic patients . Moreover, there is frequent and early disease progression in patients with HCC with higher numbers of tumor-infiltrating and circulating PD-1 + CD8+ T cells post hepatic resection . Therefore, a supporting great rationale exists for using PD-1 and PD-L-1 blocking antibodies against HCC. Some PD-1 inhibitors, such as nivolumab, pembrolizumab, and pidilizumab, have been investigated for cancer treatment.
The CheckMate-040 phase I/II trial studied the safety and antitumor effect of nivolumab in 48 patients with advanced HCC . The target population included patients with intermediate or advanced HCC and preserved liver function (Child-Turcotte-Pugh-A cirrhosis) who were candidates for systemic therapy and had progressed or were intolerant to sorafenib. In the escalation and expansion cohorts, objective tumor responses occurred in 15 and 20% of patients, respectively. There were durable responses that lasted for a median of 17 months. An additional 45% of patients had a stable disease associated with durability, lasting 6 months at minimum. Those responses were consistent across the different HCC risks, and both in sorafenib-naïve and sorafenib-exposed patients.
Overall, frequencies of grade 3/4 treatment-related AEs were 20%. Only 3% of patients discontinued nivolumab because of treatment-related adverse events, while no treatment-related deaths occurred. Elevated transaminases was the most frequent laboratory alteration (20%). However, only 5% of the patients had grade 3 or higher. Immune-related hepatitis requiring steroid therapy. CheckMate-040 showed that nivolumab might be effective with acceptable toxicity in HCC, regardless of hepatitis status. On September 22, 2017, and based on the outcome of CheckMate-040 study, the FDA granted accelerated approval to nivolumab for the treatment of hepatocellular carcinoma (HCC) as second-line therapy in patients who have been previously treated with sorafenib.
CheckMate-459 is an ongoing phase III study, (NCT02576509) that randomizes patients with advanced HCC to either nivolumab or sorafenib in the first-line setting .
The efficacy and safety of pembrolizumab in HCC has been investigated. The phase I/II study KEYNOTE-224 tested pembrolizumab in 104 patients with advanced HCC who progressed on sorafenib. The overall response rate was 16.3%. Durable response was seen with 94% of responders were estimated to have a response duration of 6 months or longer. The median PFS was 4.8 months, and the median OS was not been reached. The safety profile was generally comparable to that established for pembrolizumab monotherapy in other indications, and no viral flares were seen .
4.2.2. Oncolytic immunotherapy
Targeting tumor vasculature by oncolytic viruses (OVs) is an attractive strategy that offers several advantages. Oncolytic viruses are wild-type or engineered viruses that selectively target and replicate in cancer cells and cause lysis without harming normal tissues . The underlying mechanism of the antitumor activity for oncolytic viruses involves direct killing of tumor cells by expanding in the cells and causing cell lysis. Different from normal cell, viruses can expand in cancer cells considerably due to the impairment of the tumor’s defense mechanisms against viral infection. [40, 41, 42, 43]. In addition,, OVs can initiate antitumor immune response by triggering key signals through oncolysis to dendritic cells (DCs) and other antigen-presenting cells (APCs) . OVs have some advantages over other treatment modalities, those include: the low probability of generating resistance as OVs often target multiple oncogenic pathways; OVs replicate in a tumor-selective fashion with minimal systemic toxicities; and virus dose in the tumor increases over time due to in situ virus amplification, as opposed to classical drug pharmacokinetics that decreases with time . The efficacy of an evolutionary cancer-favoring engineered vaccinia virus (CVV) was investigated in an animal model of metastatic HCC. In this animal study, the subjects were randomized into sorafenib, CVV, or sorafenib with CVV. Metastatic regions were interestingly rare in the CVV-treated groups (i.e., CVV or sorafenib with CVV) whereas metastatic regions existed in the sorafenib-treated group .
JX-594 is a thymidine kinase gene-inactivated oncolytic vaccinia virus engineered for the expression of transgenes encoding human granulocyte-macrophage-colony-stimulating factor (GM-CSF) and β-galactosidase, which increases antitumor immune responses [39, 47, 48, 49] This virus is safe in humans and extremely toxic to cancer cells.
Oncolytic viruses have produced enough therapeutic efficacy with great optimism in the future trials. Although the initial concerns of clinical investigators were for safety like a risk of viral infection or introduce oncogenic mutation, these have proven not to be a significant issue in these trials.
4.2.3. HCC vaccines
Cancer vaccination is performed by utilizing antigenic substances to stimulate tumor-specific immune responses that can remove cancer cells and prevent recurrences. HCC vaccines include cancer cells, antigen peptides, DCs, and DNA-based.
220.127.116.11. Antigen peptide vaccines
Peptide-based tumor-associated antigens (TAAs), such as alpha-fetoprotein (AFP), GPC3, SSX-2, NY-ESO-1, human telomerase reverse transcriptase (hTERT), HCA587, and melanoma antigen gene-A (MAGE-A), are excellent vaccine targets for the treatment of HCC .
AFP which normally originates from embryonic liver cells, can be overexpressed on HCC cell surfaces. However, immune responses to AFP are limited due to acquired immune tolerance during the development of the immune system. To overcome this tolerance, a research group investigated the use of a recombinant rat AFP to induce cross-reactions between xenografts and endogenous molecules in animals and observed modest cellular and humoral immune responses . In a phase II trial of GPC3-derived peptide vaccine for HCC, 25 patients received 10 vaccinations over 1 year after surgery. The recurrence rate in patients who underwent both surgery and vaccination was significantly lower than the rate in 21 patients who underwent surgery only (24% vs. 48 and 52.4% vs. 61.9% at 1 and 2 years, p = 0 047 and 0.387, respectively), demonstrating the efficacy of the GPC3-derived vaccine .
18.104.22.168. Dendritic cell (DC) vaccines
DCs, were found to be the most powerful APCs in the body’s immune system, and capable of stimulating naïve T cells and driving primary immune responses. A phase I/IIa comparative study with 30 patients with advanced HCC stratified into mature autologous DCs pulsed, and other control group received supportive treatment. The result demonstrated an improvement in overall survival with two patients (13.3%) partial radiological response was observed, and nine patients (60%) has stable disease. The study concludes using tumor antigen-pulsed DCs vaccine can be effective adjuvant therapy with other treatment modalities of HCC or palliative treatment option in advanced HCC where other treatment options are not applicable . In addition, the safety and tolerance of DC vaccines have been confirmed in patients with HCC .
4.3. Direct immunological strategy
4.3.1. Adoptive cell therapy
Adoptive cell therapy (ACT) is an immunotherapeutic approach that attacks cancer cells using genetically engineered patients’ lymphocytes. It functions by stimulating or loading autologous lymphocytes with cytokines or tumor antigens, cultivating them ex vivo and then re-infusing them into the patient [55, 56, 57]. Adoptive immunotherapy for HCC includes cytokine-induced killer (CIK) cells, tumor-infiltrating lymphocytes (TILs), natural killer (NK) cells, and chimeric antigen receptor (CAR) T cells. The effectiveness and safety of ACT in patients with HCC have been studied in many experiments, which paved the road for its clinical implication.
22.214.171.124. Cytokine induced killer cells (CIK)
CIK cells are a heterogeneous MHC independent cell population which are able to both recognize tumor antigens and kill cancer cells directly [58, 59]. In a phase III study of adjuvant CIK therapy after radical resection for HCC, patients were randomized to receive four cycles of CIK therapy or no treatment. The median time to recurrence (TTR) was 13.6 months in the CIK group and 7.8 months in the control group (p = 0.01), All adverse events were grade 1 or 2. There were no significant differences in incidence between the two groups, indicating the safety and efficacy with respect to prolonging TTR of CIK therapy in patients with HCC. However, there were no statistically significant differences between the groups in disease-free survival (DFS) and overall survival (OS) . In addition, a meta-analysis of 693 patients with HCC demonstrated that a combination of dendritic cell- (DC-) CIK cells and TACE improves 1-and 2-year OS, overall response rate (ORR), disease control rate (DCR), and the quality of life .
126.96.36.199. Tumor infiltrating lymphocytes (TILs)
TILs are autologous tumor-infiltrating lymphocytes (TIL), which are derived from tumor tissues and are cultured and induced using IL-2 and anti-CD3 antibodies ex vivo [62, 63, 64]. Reinfusion of autologous TILs, which possess tumor-specific immunity, may target multiple tumor antigens. Low toxicity of autologous TILs was verified in a phase I study involving patients with HCC, suggesting a novel treatment option . To date, TILs have not been well characterized, mainly due to difficulties in purifying and expanding them.
188.8.131.52. Natural killer cells (NKCs)
NK cells are component of innate immune system and can directly kill tumor cells and infected cells without preliminary sensitization or MHC restriction . However, they lack the ability to target tumor cells and can injure normal liver tissues. In a previous series of experiments, the cytotoxicity of NK cells against HCC cells was enhanced by first generating a new hepatoma cell line, K562-mb15-41BBL, which achieved a more efficient stimulation of NK cells in vitro . Furthermore, HCC cells exposed to 5 μmol/L sorafenib for 48 h showed high sensitivity to NK cells. Finally, NKG2D, an engineered NK-cell-activating receptor, was tested in vitro and in mice. All of the outcomes were positive in increasing the cytotoxicity of NK cells, providing the possibility of further clinical trials in HCC.
184.108.40.206. CAR-T cell
Chimeric antigen receptor redirected-T cells (CAR-T cells) are genetically modified T lymphocytes that specifically target tumor-associated antigens (TAAs) and kill cancer cells in an MHC-independent manner [68, 69]. CAR-T cells have achieved inspiring outcomes in patients with B cell malignancies with great therapeutic efficacy in leukemia and lymphoma therapy. CAR T therapy is being studied for solid tumors, such as HCC . In some solid tumors with a tremendous phenotypic heterogeneity, CAR T cells could target the tumor antigen and cause antigen-positive cell death, while antigen-negative cancer cells may induce tumor relapse. However, Cart T cell structure engineering has been evolved significantly. Recently, CAR T cells with a transgenic “payload or TRUCK,” also called the “fourth generation” CAR T cells, were designed . This CAR T cells work by releasing inducible cytokines such as IL-12 which will augment T cell activation and further activate innate immune system to kill antigen negative cancer cells. Specific Tumor-associated antigens in HCC that recognized by cytotoxic T lymphocytes (CTLs) have been investigated. GPC3, which usually correlates with poor prognosis in HCC, has been demonstrated as a promising liver cancer-specific target in multiple studies, due to its overexpression in HCC and limited expression in normal tissues  GPC3-targeted CAR T cells could providing promising therapeutic intervention for GPC3-positive HCC. The ability of GPC3-targeted CAR T cells to eliminate GPC3-positive HCC cells was confirmed both in vivo and in vitro, and the survival of mice with HCC xenografts was prolonged with CAR T cell therapy in vivo . In another study, T cells with two complementary CARs against GPC3 and asialoglycoprotein receptor 1 (ASGR1) decreased the risk of on-target, off tumor toxicities and demonstrated potent antitumor immune responses targeting GPC3+ ASGR1+ HCCs both in vivo and in vitro . However, to date, the related studies conducted have been predominantly basic, and more clinical trials are required to prove the efficacy of CAR T in HCC.
4.4. Combination strategies
Combination therapies include combinations of different checkpoint inhibitors with TKIs, oncolytic viruses, small molecules and ablative therapies.
Combining anti-PD-1 with sorafenib has been studied in an animal model in HCC. The results showed efficacy only with the concomitant targeting of the hypoxic and immunosuppressive microenvironment with agents such as CXCR4 inhibitors, and not when combined with sorafenib alone . According to these results, a potential future approach could be by careful titration of VEGF inhibition with the aim to block the VEGF pathway and contemporarily alleviate hypoxia by vascular normalization, enhancing immunotherapy efficacy .
Checkpoint inhibitors combinations have also been studied, as a way to improve synergy and overcome resistance. PD-L1 is not the only immunosuppressive factor in the tumor microenvironment. The regulatory T cells (Treg) stands out among the immunosuppressive cells of the tumor microenvironment. Anti-CTLA-4 agents deplete tumor-associated Treg via an FccR dependant mechanism in preclinical models and have promising result in malignant melanoma .
5. Cytotoxic chemotherapies
Historically, traditional chemotherapeutic agents have not shown great efficacy in the treatment of HCC when used in the advanced disease stage, in particular in case of progression after locoregional therapy. Moreover, conventional cytotoxic chemotherapies have not provided a clinical benefit or prolonged survival for patients with advanced HCC. There are limited data supporting the use of cytotoxic chemotherapies in unresectable disease, and it should be used preferably in the context of a clinical trial .
Advanced HCC remains a deadly disease with limited systemic treatment options. The advent of sorafenib as first-line treatment ignited a plethora of trials testing various targeted and immunotherapeutic approaches. Currently, both regorafenib and nivolumab are FDA approved for second-line treatment among patients with advanced HCC who progressed on sorafenib. The list of available treatment options (Table 1) is expected to increase with the encouraging results of several ongoing early phase trials, which eventually will lead to improvement in patients survivals.
|Agent||Type||MOA||FDA Approved||Line of treatment||Trial||Positive outcome||Ref.|
|Sorafenib||MKI||VEGFRs, PDGFR, TKI||Yes||First line||SHARP||OS, PFS|||
|Lenvatinib||MKI||VEGFR, FGFR, PDGFRs, c-kit||No||First line||REFLECT||Non-inferior to sorafenib|||
|Regorafenib||MKI||VEGFR, anti-stromal TKI||Yes||Second line||RESORCE||OS, DCR|||
|Cabozantinib||MKI||VEGFR, MET, AXL c-KIT||No||Second or third line||CELESTIAL||OS|||
|Nivolumab||IgG4 McA||Anti-PD-1||Yes||Second line||CheckMate-040||DCR, OS,PFS|||
Conflict of interest
Anwaar Saeed, MD declares research grants from AstraZeneca and Exelixis.
The remaining authors declare that they have no conflict of interests.